Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 9, 2020Chief Executive Officer and Managing Director Paul Perreault will present the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.
King of Prussia, Pa. 09 Jan 2020 Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, will present at the 38th...
-
Dec 14, 2019
The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...
-
Dec 11, 2019
Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of...
-
Dec 9, 2019First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity
KING OF PRUSSIA, Pa.– December 9, 2019 – Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration...
-
Dec 9, 2019
Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine...